Author: Richard Stead

Richard B. Stead, M.D., is the founder of BioPharma Consulting Services. He provides strategic and operational advice on clinical and regulatory strategy, clinical trial design and evaluation of licensing opportunities to small biotechs and larger entities. Dr. Stead has 25 years of experience in biotechnology and drug development, directing pre-clinical research and development, clinical trials, regulatory strategy and in- and out-licensing. Dr. Stead founded BioPharma Consulting Services in 2002 to provide strategic and operational advice on clinical and regulatory strategy, clinical trial design and evaluation of licensing opportunities to small biotechs and larger entities alike. He was previously Vice President, Clinical Research at Immunex, where he was responsible for programs in oncology and inflammatory diseases, including the FDA approval of Novantrone in multiple sclerosis and studies that established the efficacy of Enbrel in psoriasis. Dr. Stead began his pharmaceutical career as Amgen’s first physician and served in various Clinical Development positions over more than 11 years, playing significant roles in the development, approval and commercialization of Amgen’s first two products, Epogen and Neupogen. He spearheaded major efforts to evaluate and in-license products at both Amgen and Immunex. Dr. Stead has a B.S. in molecular biology from the University of Wisconsin and an M.D. from Stanford University. He completed post-doctoral fellowships at Brigham & Women’s Hospital and Harvard Medical School, as well as the National Cancer Institute, before joining the faculty at the Fred Hutchinson Cancer Research Center. Dr. Stead has authored a number of papers in peer-reviewed publications including Blood, the New England Journal of Medicine and the Proceedings of the National Academy of Sciences.